Mabpharm (HKSE:02181) Days Payable : 420.29 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Days Payable?

Mabpharm's average Accounts Payable for the six months ended in Dec. 2023 was HK$14.42 Mil. Mabpharm's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$6.26 Mil. Hence, Mabpharm's Days Payable for the six months ended in Dec. 2023 was 420.29.

The historical rank and industry rank for Mabpharm's Days Payable or its related term are showing as below:

HKSE:02181' s Days Payable Range Over the Past 10 Years
Min: 187.49 Med: 364.27 Max: 441.88
Current: 441.88

During the past 7 years, Mabpharm's highest Days Payable was 441.88. The lowest was 187.49. And the median was 364.27.

HKSE:02181's Days Payable is ranked better than
73.41% of 722 companies
in the Biotechnology industry
Industry Median: 148.53 vs HKSE:02181: 441.88

Mabpharm's Days Payable declined from Dec. 2022 (990.17) to Dec. 2023 (420.29). It may suggest that Mabpharm accelerated paying its suppliers.

Mabpharm Days Payable Historical Data

The historical data trend for Mabpharm's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Days Payable Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

187.49

364.27

412.45

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial								215,030.63	349.26	990.17	490.14	420.29

Competitive Comparison of Mabpharm's Days Payable

For the Biotechnology subindustry, Mabpharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Days Payable distribution charts can be found below:

* The bar in red indicates where Mabpharm's Days Payable falls into.

Mabpharm Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Mabpharm's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (18.522	+	10.951)	/	2 )	/	13.041	*	365
=	14.7365					/	13.041	*	365
=	412.45

Mabpharm's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (17.891	+	10.951)	/	2 )	/	6.262	*	365 / 2
=	14.421					/	6.262	*	365 / 2
=	420.29

Mabpharm Days Payable Related Terms

Thank you for viewing the detailed overview of Mabpharm's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines